Netupitant

奈妥吡坦

Report date: 2022/09/08 17:46:58
NME

Base Information

Drug NameNetupitant
Drug Alias Namenetupitantum奈妥匹坦netupitantR-1124Ro-67-3189/000 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonists
TargetsNeurokinin 1 receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu shengdi Medicine Co LtdInstituto Brasileiro De Controle Do Cancer
Inactive CompaniesOhsu Knight Cancer InstituteJiangsu Simcere Pharmaceutical Co LtdHelsinn Healthcare Sa
Active IndicationsChemotherapy-induced nausea and vomiting
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG